Answers are grounded in this paper and cite their sources.
Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood and is cured by application of modern treatment protocols in more than 80% of cases. 1 , 2 However, the ~20% of children with ALL suffering from relapse still exemplify the ongoing need for improved risk stratification and adapted treatment strategies. 1 , 2 In several studies, deletions of IKZF1 —encoding IKAROS, a transcription factor important for lymphoid development and differentiation—have been associated with a poor treatment outcome in precursor B cell ALL. 3 , 4 , 5 Deletions of IKZF1 are observed in 10–15% of pediatric ALLs and affect either the entire IKZF1 gene or appear as focal deletions. 3 , 4 , 5 The most common of the latter ones (Δ4–7) includes the DNA-binding region and results in a dominant-negative isoform (Ik6), impairing cell differentiation in CD34+ lymphoid progenitor cells. 3 , 4 , 5
No takes yet. Share an insight, caveat, or question.
Hinze et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: